The introduction of synthetic nicotine alternatives like 6-methyl nicotine in vapes is raising concerns due to their potential higher potency and addictive nature compared to traditional nicotine. The FDA and researchers are investigating these compounds, but current data is insufficient. Regulatory gaps allow these products to be marketed without FDA authorization, posing risks to consumers.
BioCorRx Pharmaceuticals Inc Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translati.